Huang J, Schreiber SL. A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. Proc Natl Acad Sci U S A. 1997;94(25):13396-401.
Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141). doi:10.1098/rsif.2017.0387
Crabtree GR, Schreiber SL. Three-part inventions: intracellular signaling and induced proximity. Trends Biochem Sci. 1996;21(11):418-22.
Palmer WS, Poncet-Montange G, Liu G, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016;59(4):1440-54. doi:10.1021/acs.jmedchem.5b00405
Feng S, Kapoor TM, Shirai F, Combs AP, Schreiber SL. Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis. Chem Biol. 1996;3(8):661-70.
Silva AF, Torres MDT, Silva LS, et al. Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction. Sci Rep. 2017;7(1):14326. doi:10.1038/s41598-017-14642-z
Luo X, Liu Y, Kubicek S, et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc. 2011;133(24):9451-6. doi:10.1021/ja201597b
Wellington S, Hung DT. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets. ACS Infect Dis. 2018;4(5):696-714. doi:10.1021/acsinfecdis.7b00255
Peng LF, Kim SS, Matchacheep S, et al. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob Agents Chemother. 2007;51(10):3756-9. doi:10.1128/AAC.00233-07
Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat Rev Drug Discov. 2018;17(5):333-352. doi:10.1038/nrd.2018.53